Navigation Links
NCCN Stresses Importance of PSA Testing in High-Risk Men
Date:8/10/2009

e National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center / Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Insti
'/>"/>

SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
2. Nutrition model stresses positive experience of eating
3. Ancient mechanism for coping with stresses also gives cancer a boost
4. PDA Stresses Importance of Good Nutrition
5. Dr. Louis Sullivans Symphony of Health Care Delivery Stresses Importance of Communication, Quality Research in Health Care
6. American Red Cross Stresses Family Preparedness During National Fire Prevention Week, Oct. 7-13
7. PDA Stresses Link Between Oral Health and Overall Health
8. What Stresses Teens Out
9. Workplace opportunities and stresses are both increasing
10. National Cervical Cancer Coalition Stresses Importance of Screening and Prevention During January Cervical Health Awareness Month
11. American Dental Association Stresses Good Oral Health During Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 1Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 2Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 3Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 4Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 5Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 6Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study 5663 1Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study 5663 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 1NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 3
Other Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8